An Updated and Focused Review on Heterocyclic Inhibitors for SARS-CoV and SARS-CoV-2 3CLpro

被引:1
|
作者
Manaithiya, Ajay [1 ]
Alam, Ozair [1 ]
Mittal, Shruti [1 ]
Naim, Mohd. Javed [1 ]
Imran, Mohd [2 ]
Alshrari, Ahmed Subeh [3 ]
Sheikh, Aadil A. A. [1 ]
Khan, Imran A. A. [4 ]
机构
[1] Jamia Hamdard, Sch Pharmaceut Educ & Res, Med Chem & Mol Modelling Lab, Dept Pharmaceut Chem, New Delhi 110062, India
[2] Northern Border Univ, Fac Pharm, Dept Pharmaceut Chem, Rafha 91911, Saudi Arabia
[3] Northern Border Univ, Fac Appl Med Sci, Med Lab Technol, Ar Ar, Saudi Arabia
[4] Jamia Hamdard, Sch Chem & Life Sci, Dept Chem, New Delhi 110062, India
关键词
SARS-CoV; SARS-CoV-2; biological activity; structure-activity relationship; molecular docking; heterocyclic inhibitors; ACUTE RESPIRATORY SYNDROME; 3CL PROTEASE INHIBITORS; CORONAVIRUS DISEASE 2019; ANTIVIRAL ACTIVITY; BIOLOGICAL EVALUATION; ISATIN DERIVATIVES; COVID-19; INFECTION; VIRAL-RNA; IN-VITRO; IDENTIFICATION;
D O I
10.2174/1389557522666220511125102
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background SARS-CoV and SARS-CoV-2 are exceedingly contagious and typically result in major respiratory illnesses (acute respiratory syndrome). The public health is facing enormous challenges across all the nations due to these newly emerging pathogens. Reliable and systematic examination of SARS-CoV and COVID-19 will assist in identifying infectious persons accurately. Based on the biological, chemical, and genetic link of SARS CoV-2 towards SARS-CoV, the recurrence of different anti-SARS-CoV natural drug molecules may be beneficial in the advancement of anti-COVID-19 herbal drug molecules. Here in this review, we evaluated SAR research that has recently been published as well as molecular docking analysis of previously synthesised compounds that have been targeted against SARS-CoV and SARS-CoV-2, respectively. This investigation might assist scientists in creating novel and revolutionary molecules that could target SAR-CoV-2. Objectives The review highlights the heterocyclic inhibitors' ability to successfully inhibit SARS-CoV and SARS-CoV-2. The meticulously described structure-activity relationship of potential SARS-CoV and SARS-CoV-2 inhibiting compounds has been addressed in this review. Evidence Acquisition We conducted a thorough literature assessment employing electronic databases for scientific articles highlighting potential heterocyclic inhibitors for SARS-CoVand SARS-CoV-2, published from 2010 to 2021. We recovered 415 articles, but only 220 were involved and conversed in this manuscript. The article apprehended appropriate research considering three areas: 1) SAR activity, 2) Molecular docking, and 3) Biological activity and future prospects on SARS-CoV-2. Methods The potential compounds with decent inhibitory activity have been discussed and reviewed along with their inhibition potential, expressed in terms of IC50 value. Results Heterocyclic scaffolds reflect an extensive spectrum of therapeutic activity and might function as an initiating concept for the designing and discovery of potential inhibitors for SARS-CoV and SARS-CoV-2 treatment. Conclusion The points highlighted here may prove to be a vital tool for medicinal chemists working/investigating more potent and efficacious scaffolds in treating SARS-CoV and SARS-CoV-2.
引用
收藏
页码:576 / 632
页数:57
相关论文
共 50 条
  • [1] Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
    Zhu, Jiajie
    Zhang, Haiyan
    Lin, Qinghong
    Lyu, Jingting
    Lu, Lu
    Chen, Hanxi
    Zhang, Xuning
    Zhang, Yanjun
    Chen, Keda
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1067 - 1082
  • [2] Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations
    Tiyoula, Fereshteh Noroozi
    Aryapour, Hassan
    PLOS ONE, 2022, 17 (02):
  • [3] Profiling of Substrate Specificity of SARS-CoV 3CLpro
    Chuck, Chi-Pang
    Chong, Lin-Tat
    Chen, Chao
    Chow, Hak-Fun
    Wan, David Chi-Cheong
    Wong, Kam-Bo
    PLOS ONE, 2010, 5 (10):
  • [4] SARS-CoV-2 3CLpro displays faster self-maturation in vitro than SARS-CoV 3CLpro due to faster C-terminal cleavage
    Kuo, Chih-Jung
    Liang, Po-Huang
    FEBS LETTERS, 2022, 596 (09) : 1214 - 1224
  • [5] Geraniin as a potential inhibitor of SARS-CoV-2 3CLpro
    Yu, Wen-Di
    Jin, Qi-Ying
    Zeng, Mao-Sen
    Liu, Jin-Yuan
    Xu, Pei-Ping
    NATURAL PRODUCT RESEARCH, 2022, 36 (23) : 6060 - 6063
  • [6] Protocol for production and purification of SARS-CoV-2 3CLpro
    Mazzei, Luca
    Greene-Cramer, Rebecca
    Bafna, Khushboo
    Jovanovic, Aleksandar
    De Falco, Anna
    Acton, Thomas B.
    Royer, Catherine Ann
    Ciurli, Stefano
    Montelione, Gaetano T.
    STAR PROTOCOLS, 2023, 4 (02):
  • [7] Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors
    Nukoolkarn, Veena
    Lee, Vannajan Sanghiran
    Malaisree, Maturos
    Aruksakulwong, Ornjira
    Hannongbua, Supot
    JOURNAL OF THEORETICAL BIOLOGY, 2008, 254 (04) : 861 - 867
  • [8] Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CLpro inhibitors
    Wang, Feng
    Liu, Donglan
    Gao, Dingding
    Yuan, Jinwei
    Zhao, Jingxian
    Yuan, Shuai
    Cen, Yixin
    Lin, Guo-Qiang
    Zhao, Jincun
    Tian, Ping
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 264
  • [9] Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro
    Ma, Ling
    Li, Quanjie
    Xie, Yongli
    Zhao, Jianyuan
    Yi, Dongrong
    Guo, Saisai
    Guo, Fei
    Wang, Jing
    Yang, Long
    Cen, Shan
    ANTIVIRAL RESEARCH, 2022, 207
  • [10] Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
    Kuang, Yi
    Ma, Xiaodong
    Shen, Wenjing
    Rao, Qingqing
    Yang, Shengxiang
    FUTURE SCIENCE OA, 2023, 9 (04):